Raymond James upgrades Dianthus stock on CIDP trial results
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices sink as Trump talks Iran war end, supply relief Gold prices rise but still rangebound with focus on Iran war de-escalation Aramco tops forecasts, warns of ‘catastrophic’ fallout from Hormuz disruption Futures rise as Trump says Iran war will end "very soon" - what’s moving markets (South Africa Philippines Nigeria) Raymond James upgrades Dianthus stock on CIDP trial results By Analyst Ratings Published 03/10/2026, 05:03 AM Raymond James upgrades Dianthus stock on CIDP trial results 0 DNTH 21.52% Investing.com - Raymond James upgraded Dianthus Therapeutics (NASDAQ:DNTH) to Strong Buy from Outperform on Tuesday and raised its price target to $123 from $63. The stock surged 43% over the past week to $79.23, bringing the year-to-date gain to 92% and pushing the company’s market capitalization to $3.5 billion. The upgrade follows an interim update from the pivotal Phase 3 CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy patients. The responder rate in Part A of the study exceeded 50% in all-comer patients. Raymond James said the development is likely to shorten clinical development in CIDP and reduce the time-to-market gap between Dianthus and Sanofi’s riliprubart. Management scaled down overall study enrollment following the results. The firm cited the positive CIDP data along with last year’s positive generalized myasthenia gravis Phase 2 readout as increasing conviction in claseprubart. While InvestingPro analysis suggests the stock is currently overvalued based on its Fair Value assessment, two analysts have recently revised their earnings estimates upward for the upcoming period. A Phase 2 proof-of-concept readout for a third indication, multifocal motor neuropathy, is expected in the second half of 2026. Dianthus plans to release initial data from the Phase 1 study of DNTH212 in healthy volunteers and initiate a Phase 3 program in generalized myasthenia gravis in mid-2026, with...
Read full article at source